Mitochon Pharmaceuticals

United States
Radnor, Pennsylvania, United States, 19087

Company profile

Mitochon Pharmaceuticals company profile

Mitochon Pharmaceuticals is a start-up biotech company, formed in 2014, that focuses on developing drugs that target the mitochondria for a host of serious diseases with significant unmet medical needs. Their development programs are primarily focused on neurodegenerative & neuromuscular diseases including: Huntington’s, Batten Disease, Stroke, Duchenne Muscular Dystrophy (DMD), Alzheimer’s Disease, Parkinson Disease and severe burns, and secondarily on metabolic disorders due to over-nutrition (diabetes, obesity and NASH). On-going research has linked these diseases to various malfunctions of the mitochondria. By correcting them, Mitochon aims at opening the way for a broad range of disease modifying therapies. Mitochon is led by a team of industry executives with over 80-years of combined experience and a passion to bring forward breakthrough drug therapies for a host of devastating diseases.

Business identity

Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$1M-$10M
Founded
2014-01-01, Year

Headquarters

Postal code
19087
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
3
Total equity funding
$1.9M
Last funding
Series Unknown / $1.6M / 2016-05-17
Last equity funding
Series Unknown / $1.6M
Investors
1
Lead investors
1
Founders
2
Articles
12

Founders and investors

Founders

John G. GeislerRobert Alonso

Lead investors

Ben Franklin Technology Partners of Southeastern Pennsylvania

Investors

Ben Franklin Technology Partners of Southeastern Pennsylvania